BACKGROUND: Rezum is a novel minimally invasive surgical technique (MIST) useful for BPH patients with medium-sized prostate (30-80 cm(3)) refractory to medical treatment. The aim of this study was to evaluate the efficacy and safety of Rez & umacr;m as a treatment option in large-sized prostates (>80 cm(3)). METHODS: We performed a prospective, comparative, single-center study from June 2022 to June 2023, including con- secutive patients undergoing surgery with the Rez & umacr;m System. Enrolled men were classified into two subgroups based on prostate size: medium prostate (MP) (30-80 cm(3)) and large prostate (LP) (>80 cm(3)). Inclusion criteria included an Interna- tional Prostate Symptom Score (IPSS) Total score of > 8 points. International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), post-void residual (PVR), and International Index of Erectile Function 5-item version (IIEF-5) were collected at baseline and at three, six, and 12 months post-procedure. Ejaculation presence was assessed at 3 months. Post-operative complications were described using the Clavien-Dindo (CD) classification. The primary outcome was the IPSS-Total score, with intraoperative and postoperative CD grade >III complications as secondary outcomes. RESULTS: One hundred and twenty-one patients (PV 78.2 +/- 32.1 mL) were included in the study, 51 large prostate (LP) and 70 medium prostate (MP). The IPSS-Total score and Q(max )showed a statistically significant (P<0.0001) improvement at 3, 6, and 12 months respectively. PVR decreased at 3, 6, and 12 months; however, only at 3 months this variation was statistically significant (P<0.0001). At 3-month follow-up, anejaculation was detected in (3; 5.8% and 1; 1.4%) patients in LP and MP group respectively (P=0.86). IIEF-5 significantly improved 3 months after surgery in the LP subgroup (P<0.0001). CONCLUSIONS: Rezum water vapor therapy appears to be effective for treating BPH in larger prostates. Additionally, it demonstrates a low risk of impairing sexual function, indicating a favorable safety profile.

Water vapor thermal therapy (Rezūm System) in patients with large prostates: results from a prospective comparative study

FUSCO, Ferdinando;ARCANIOLO, Davide;MANFREDI, Celeste;
2024

Abstract

BACKGROUND: Rezum is a novel minimally invasive surgical technique (MIST) useful for BPH patients with medium-sized prostate (30-80 cm(3)) refractory to medical treatment. The aim of this study was to evaluate the efficacy and safety of Rez & umacr;m as a treatment option in large-sized prostates (>80 cm(3)). METHODS: We performed a prospective, comparative, single-center study from June 2022 to June 2023, including con- secutive patients undergoing surgery with the Rez & umacr;m System. Enrolled men were classified into two subgroups based on prostate size: medium prostate (MP) (30-80 cm(3)) and large prostate (LP) (>80 cm(3)). Inclusion criteria included an Interna- tional Prostate Symptom Score (IPSS) Total score of > 8 points. International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), post-void residual (PVR), and International Index of Erectile Function 5-item version (IIEF-5) were collected at baseline and at three, six, and 12 months post-procedure. Ejaculation presence was assessed at 3 months. Post-operative complications were described using the Clavien-Dindo (CD) classification. The primary outcome was the IPSS-Total score, with intraoperative and postoperative CD grade >III complications as secondary outcomes. RESULTS: One hundred and twenty-one patients (PV 78.2 +/- 32.1 mL) were included in the study, 51 large prostate (LP) and 70 medium prostate (MP). The IPSS-Total score and Q(max )showed a statistically significant (P<0.0001) improvement at 3, 6, and 12 months respectively. PVR decreased at 3, 6, and 12 months; however, only at 3 months this variation was statistically significant (P<0.0001). At 3-month follow-up, anejaculation was detected in (3; 5.8% and 1; 1.4%) patients in LP and MP group respectively (P=0.86). IIEF-5 significantly improved 3 months after surgery in the LP subgroup (P<0.0001). CONCLUSIONS: Rezum water vapor therapy appears to be effective for treating BPH in larger prostates. Additionally, it demonstrates a low risk of impairing sexual function, indicating a favorable safety profile.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11591/547658
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 2
social impact